162 related articles for article (PubMed ID: 16273350)
1. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.
Osada T; Clay T; Hobeika A; Lyerly HK; Morse MA
Cancer Immunol Immunother; 2006 Sep; 55(9):1122-31. PubMed ID: 16273350
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
[TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide.
Sakakibara M; Kanto T; Hayakawa M; Kuroda S; Miyatake H; Itose I; Miyazaki M; Kakita N; Higashitani K; Matsubara T; Hiramatsu N; Kasahara A; Takehara T; Hayashi N
Cancer Immunol Immunother; 2011 Nov; 60(11):1565-75. PubMed ID: 21681375
[TBL] [Abstract][Full Text] [Related]
5. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
Pilla L; Squarcina P; Coppa J; Mazzaferro V; Huber V; Pende D; Maccalli C; Sovena G; Mariani L; Castelli C; Parmiani G; Rivoltini L
Cancer Res; 2005 May; 65(9):3942-9. PubMed ID: 15867395
[TBL] [Abstract][Full Text] [Related]
6. Helper role of NK cells during the induction of anticancer responses by dendritic cells.
Kalinski P; Giermasz A; Nakamura Y; Basse P; Storkus WJ; Kirkwood JM; Mailliard RB
Mol Immunol; 2005 Feb; 42(4):535-9. PubMed ID: 15607810
[TBL] [Abstract][Full Text] [Related]
7. Role of natural killer cell function in dendritic cell-based vaccines.
Woo CY; Clay TM; Lyerly HK; Morse MA; Osada T
Expert Rev Vaccines; 2006 Feb; 5(1):55-65. PubMed ID: 16451108
[TBL] [Abstract][Full Text] [Related]
8. [The effect of tumor-dendritic cell fusion vaccines on the cytotoxicity of CIK/NK cells from cord blood].
Li Y; Huang SL; Wu YF; Wei J; Meng Y; Zhou DH; Bao R
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):269-72. PubMed ID: 15949286
[TBL] [Abstract][Full Text] [Related]
9. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity.
Yamaguchi S; Tatsumi T; Takehara T; Sasakawa A; Hikita H; Kohga K; Uemura A; Sakamori R; Ohkawa K; Hayashi N
Cancer Immunol Immunother; 2008 Dec; 57(12):1861-9. PubMed ID: 18438665
[TBL] [Abstract][Full Text] [Related]
12. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
13. A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.
Hanson MG; Ozenci V; Carlsten MC; Glimelius BL; Frödin JE; Masucci G; Malmberg KJ; Kiessling RV
Cancer Immunol Immunother; 2007 Jul; 56(7):973-84. PubMed ID: 17143612
[TBL] [Abstract][Full Text] [Related]
14. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
15. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
[TBL] [Abstract][Full Text] [Related]
16. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract][Full Text] [Related]
17. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
[TBL] [Abstract][Full Text] [Related]
18. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
[TBL] [Abstract][Full Text] [Related]
19. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
20. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
